Page 1

EX - 99.1 2 exhibit991q12021 earningspr.htm EX - 99.1 E OFEM BIOSCIENCE SⓇ Exhibit 99.1 -- Evofem Biosciences Reports First Quarter 2021 Financial Results and Provides Corporate Update - Net Revenues Increased 550 % Compared to 2020 Fourth Quarter -- - Over 5,000 Healthcare Providers have Prescribed Phexxi to Date -- -- Management to Host Conference Call Today , Thursday , May 6 , 2021 , at 4:30 p.m. ET -- SAN DIEGO , May 6 , 2021 - Evofem Biosciences , Inc. , ( NASDAQ : EVFM ) ( " Evofem " or the " Company " ) , today reported financial results for the three - month period ended March 31 , 2021 . First quarter and recent highlights include : • • • • • Direct - to - consumer ( DTC ) marketing campaign launched on February 14 , 2021 resulting in : ° 0 83 % total prescription growth for Phexxi® ( lactic acid , citric acid and potassium bitartrate ) in March vs. February ; A 78 % increase in healthcare providers prescribing Phexxi in March vs. February ; Expanded Phexxi total brand awareness growth , reaching 12 % in March vs. 4 % in January ; Net revenues increased to $ 1.1 million compared to $ 0.2 million in the fourth quarter of 2020 ; Advanced enrollment in EVOGUARD , the pivotal Phase 3 clinical trial evaluating safety and efficacy of EVO100 for the prevention of chlamydia and gonorrhea in women , toward goal of completing enrollment by year - end 2021 ; American Journal of Obstetrics and Gynecology published the Phase 2b / 3 AMPREVENCE clinical trial manuscript ; this double - blinded , placebo - controlled study of EVO100 met its primary and secondary efficacy endpoints , with statistically significant reductions in the risk of chlamydia and gonorrhea infections . Data sets from the Phase 3 AMPOWER trial of Phexxi for prevention or pregnancy were presented in April 2021 at the American College of Obstetricians and Gynecologists ( ACOG ) and National Community Oncology Dispensing Association ( NCODA ) annual meetings . “ Our ' Get Phexxi ' DTC campaign launched nationwide on Valentine's Day , resulting in strong first quarter growth . More than 5,000 healthcare providers have prescribed Phexxi to date , and Phexxi prescriptions increased 83 % from February to March , " said Saundra Pelletier , Evofem's Chief Executive Officer . " Contraception is the most promotionally - sensitive pharmaceutical category , and we expect this ongoing campaign will continue to drive Phexxi uptake . ”